Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
2
in the last 3 days
First reported
4 days ago
1 outlets since
Countries
1 other outlets reported this story in the last 3 days.
DexCom (DXCM) is back in focus after Citi highlighted the medtech group’s revenue growth, its raised guidance for a second straight quarter, and its expanding reach among Type 2 diabetes patients using its glucose monitoring products. Over the past year, momentum in DexCom has been uneven. The share price return is up…